InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with BeOne Medicines, a global oncology company.
In this project mechanistic translational modeling will be applied to support selection of minimal recommended starting dose and step-up dosing regimen to mitigate cytokine release syndrome and optimize dose-escalation clinical study design.
"Nowadays, trimer-based mechanistic modeling has become an essential tool to guide the selection of an appropriate starting dose for first-in-human trials of T-cell engagers, ensuring the dose is high enough to be effective while avoiding sub-therapeutic levels and multiple dose escalation steps," said Oleg Demin Jr, Head of Oncology and Immuno-Oncology, InSysBio. "InSysBio's generic QSP model for T-cell engagers mechanistically captures the difference between in vitro and clinical settings, supporting precise preclinical-to-clinical translation. Consequently, it allows prediction of not only the starting dose but also the step-up dosing regimen based on preclinical data."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
1.
09 Mar 2017 14:10
ISBM Enclosed Conference was held
20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.
|
10
|
11
|
12
|
|
13
|
14
|
15
1.
15 Mar 2017 11:49
Institute for Systems Biology participates in American Society for Clinical Pharmacology and Therapeutics 2017 Meeting
Institute for Systems Biology Moscow – a company, providing modeling services for innovative drug design, announced participation in ASCPT 2017 Meeting, which is held on 15-18 March in Washington, DC. ISBM will present several studies and demonstrate an updated version of platform for quantitative systems pharmacology modeling of immune response - Immune Response Template (IRT).
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
1.
28 Mar 2017 17:56
Not all therapies are effective: Institute for Systems Biology Moscow to present the results of the Alzheimer’s disease Systems Pharmacology Modeling
Moscow, Russia – March 28, 2017. On the 1st April, Tatyana Karelina, ISBM leading specialist in neurodegenerative field, will present a poster entitled "Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model" at the 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders to be held on March 29 - April 2, Vienna, Austria.
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
